Loading
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Latest filing published 18 Nov 2025 for Bioxytran, INC, €12k.
Insider track record
Disclosed buys
6
Disclosed sells
0
Signal history
Closed purchases
Market purchases
6
Positive at T+90
25%
Median T+90
-13.5%
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -34.8%Entry US$4.14 · Close at T+365 US$2.70
- -57.4%Entry US$5.64 · Close at T+365 US$2.40
- -66.7%Entry US$7.20 · Close at T+365 US$2.40
- +14.5%Entry US$3.30 · Close at T+365 US$3.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Dale H. Conaway: trading record in brief
Dale H. Conaway is a declared insider at 3 companies; the most frequent names are Bioxytran, Inc, Galectin Therapeutics Inc and NANOMIX Corp. We count 23 filings; the first trade dates from 8 February 2007 and the latest from 14 November 2025.
No open-market sale appears; the market trades are 6 purchases worth €4,581. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 15 share grants.
In size, the median ticket on the buying side is €375. Ninety days after publication, 4 purchases show a median change of -13.5%, with the price up in 25% of them. This is a record of the past, not a forecast.
The record was last updated on 18 November 2025 with a share grant (€12k) in Bioxytran, Inc. The most recent open-market purchase was published on 8 June 2015, 4,157 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Dale H. Conaway
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations22 total
38,588 shares@ US$0.352.2% of flowpreferredSEC:0001445815-25-000009:1
10,417 shares@ US$0.4850.9% of flowpreferredSEC:0001445815-25-000009:0
97,535 shares@ US$0.3156.5% of flowPreferredSEC:0001754429-25-000003:0
20,619 shares@ US$0.461.9% of flowpreferredSEC:0001754429-24-000010:0
123,967 shares@ US$0.1213.0% of flowcommonSEC:0001754429-24-000002:0
1,060,089 shares@ US$0.16734.7% of flowcommonSEC:0001754429-24-000002:1
212,018 shares@ US$0.83534.7% of flowpreferredSEC:0001754429-24-000002:2
70,423 shares@ US$0.1422.0% of flowcommonSEC:0001445815-24-000012:0
266,955 shares@ US$0.1146.1% of flowcommonSEC:0001445815-24-000008:0
77,721 shares@ US$0.1933.1% of flowcommonSEC:0001445815-23-000023:0
40,000 shares@ US$0.151.2% of flowcommon stockSEC:0001445815-23-000017:0
30,000 shares@ US$0.4482.7% of flowCommon StockSEC:0001445815-23-000010:0
50,000 shares@ US$0.232.4% of flowCommon StockSEC:0001636357-22-000002:0
80,000 shares@ US$0.0010.0% of flowCommonSEC:0001539497-22-000079:1
30,000 shares@ US$0.170.9% of flowCommonSEC:0001539497-22-000079:0
227,800 shares@ US$0.248.9% of flowCommonSEC:0001785982-21-000025:0
22,000 shares@ US$0.0060.0% of flowCommonSEC:0001785982-20-000997:0
5,000 shares@ US$0.12Common StockSEC:0001102624-15-000932:0
Canonical exit: 13 Aug 2015 (T+90)
400 shares@ US$0.75Common StockSEC:0001181431-07-022616:0
Canonical exit: 27 Jun 2007 (T+90)
2,000 shares@ US$1.08Common StockSEC:0001181431-07-018011:0
Canonical exit: 3 Jun 2007 (T+90)
60 shares@ US$1.20Common StockSEC:0001181431-07-014539:0
Canonical exit: 16 May 2007 (T+90)
7,500 shares@ US$0.36Common StockSEC:0001181431-07-010182:0
Canonical exit: 9 May 2007 (T+90)
22 of 22 declarations
